Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical Outcome
Journal of Interventional Cardiology · 20.12.2022 · 2022 · 1-8
DOI: 10.1155/2022/5223317 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Interventional Cardiology, erschienen am 20.12.2022. Verfasst von Piotr Rola und 12 weiteren Autor:innen. Beteiligte Einrichtung: Witelon Collegium State University, 59-220 Legnica, Poland. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Percutaneous Coronary Intervention, Drug-Eluting Stents, Coronary Artery Disease. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Percutaneous coronary intervention (PCI) in the acute coronary syndrome (ACS) setting is associated with a greater probability of device failure. The currently ongoing development of new scaffold technologies has concentrated an effort on improving the PCI outcomes, including the use of new biodegradable materials. This pilot study evaluates the performance of a magnesium bioresorbable scaffold (Magmaris, Biotronik, Germany) in comparison to the sirolimus‐eluting bioresorbable polymer stents (BP-SES) (Ultimaster, Terumo, Japan) in the NSTE-ACS setting.
Methods
The population of this pilot comprised 362 patients assigned to one of two arms (193-Magmaris vs 169-Ultimaster). The data regarding the primary outcome comprised of death from cardiac causes, myocardial infarction, and stent thrombosis, along with target-lesion failure (TLF) and other clinical events was collected in the 1-yearfollow-up.
Results
There were no statistically significant differences in clinical outcomes in the short term (30 days) or in the 1-yearfollow-up between both groups.
Conclusion
At 12 months, there were no statistically significant differences between the Magmaris and Ultimaster for composed endpoints or the TLF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Witelon Collegium State University, 59-220 Legnica, Poland.
- Department of Cardiology, Provincial Specialized Hospital in Legnica, 59-220 Legnica, Poland.
- Department of Cardiology, The Copper Health Centre (MCZ), 59-300 Lubin, Poland.
- Adalbert's Hospital, 61-144 Poznan, Poland.
- Faculty of Mathematics and Information Science, Warsaw University of Technology, 00-662 Warsaw, Poland.
- Faculty of Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland.
ORCID-Profile: Piotr Rola, Adrian Włodarczak, Szymon Włodarczak, Mateusz Barycki, Marek Szudrowicz, Magdalena Łanocha, Łukasz Furtan, Katarzyna Woźnica, Jan Jakub Kulczycki, Michalina Kędzierska, Adrian Doroszko, Maciej Lesiak
Zitieren
APA
Rola, P., Włodarczak, A., Włodarczak, S., Barycki, M., Szudrowicz, M., Łanocha, M., Furtan, Ł., Woźnica, K., Kulczycki, J. J., Jaroszewska-Pozorska, J., Kędzierska, M., Doroszko, A., & Lesiak, M. (2022). Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical Outcome. Journal of Interventional Cardiology, 2022, 1-8. https://doi.org/10.1155/2022/5223317
Vancouver
Rola P, Włodarczak A, Włodarczak S, Barycki M, Szudrowicz M, Łanocha M, et al. Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical Outcome. Journal of Interventional Cardiology. 2022;2022:1-8. doi:10.1155/2022/5223317
BibTeX
@article{Rola2022,
author = {Rola, Piotr and Włodarczak, Adrian and Włodarczak, Szymon and Barycki, Mateusz and Szudrowicz, Marek and Łanocha, Magdalena and Furtan, Łukasz and Woźnica, Katarzyna and Kulczycki, Jan Jakub and Jaroszewska-Pozorska, Joanna and Kędzierska, Michalina and Doroszko, Adrian and Lesiak, Maciej},
title = {Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical Outcome},
journal = {Journal of Interventional Cardiology},
year = {2022},
volume = {2022},
pages = {1--8},
doi = {10.1155/2022/5223317}
}
EUVIMED